Abstract:Purpose or the research: Nearly 300,000 people are affected by spinal cord injury (SCI) with approximately 18,000 new cases annually, according to the National SCI Statistics Center. SCI affects physical mobility and impairs the function of multiple internal organs to cause lower urinary tract (LUT) dysfunctions manifesting as detrusor sphincter dyssynergia (DSD) and neurogenic detrusor overactivity (NDO) with detrimental consequences to the quality of life and increased morbidity. Multiple lines of evidence now support time dependent evolution of the complex SCI pathology which requires a multipronged treatment approach of immediate, specialized care after spinal cord trauma bookended by physical rehabilitation to improve the clinical outcomes. Instead of one size fits all treatment approach, we propose adaptive drug treatment to counter the time dependent evolution of SCI pathology, with three small molecule drugs with distinctive sites of action for the recovery of multiple functions. Principal results: Our findings demonstrate the improvement in the recovery of hindlimb mobility and bladder function of spinal cord contused mice following administration of small molecules targeting neurotrophin receptors, LM11A-31 and LM22B-10. While LM11A-31 reduced the cell death in the spinal cord, LM22B-10 promoted cell survival and axonal growth. Moreover, the soluble guanylate cyclase (sGC) activator, cinaciguat, enhanced the revascularization of the SCI injury site to promote vessel formation, dilation, and increased perfusion. Major conclusions: Our adaptive three drug cocktail targets different stages of SCI and LUTD pathology: neuroprotective effect of LM11A-31 retards the cell death that occurs in the early stages of SCI; and LM22B-10 and cinaciguat promote neural remodeling and reperfusion at later stages to repair spinal cord scarring, DSD and NDO. LM11A-31 and cinaciguat have passed phase I and IIa clinical trials and possess significant potential for accelerated clinical testing in SCI/LUTD patients.

Mechanisms of nitric oxide in spinal cord injury

Inflammation & apoptosis in spinal cord injury.

The Role of Purinergic Receptors in Neural Repair and Regeneration after Spinal Cord Injury

The Role of Nitric Oxide and Hydrogen Sulfide in Spinal Cord Injury: an Updated Review

A Brief Summary of Current Therapeutic Strategies for Spinal Cord Injury

Role of inflammation in neurological damage and regeneration following spinal cord injury and its therapeutic implications

Inflammatory Response to Spinal Cord Injury and Its Treatment

Acute Spinal Cord Injury, Part I: Pathophysiologic Mechanisms

Recent advances in the application of gasotransmitters in spinal cord injury

Wnt signaling pathway in spinal cord injury: from mechanisms to potential applications

Spinal cord injury: molecular mechanisms and therapeutic interventions

Acute Spinal Cord Injury: Pathophysiology and Pharmacological Intervention (Review).

Inflammogenesis of Secondary Spinal Cord Injury

CHANGES OF NITRIC OXIDE SYNTHASE NEURONS IN SPINAL CORD INJURY OF RATS

Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration

Notoginsenoside R1 Alleviates Spinal Cord Injury by Inhibiting Oxidative Stress, Neuronal Apoptosis, and Inflammation via Activating the Nrf2/HO-1 Signaling Pathway

Recent advances in nanomaterials for the treatment of spinal cord injury

Targeting neurotrophin and nitric oxide signaling to treat spinal cord injury and associated neurogenic bladder overactivity

Advances in Novel Biomaterial-Based Strategies for Spinal Cord Injury Treatment

Sirtuins: Potential Therapeutic Targets for Defense Against Oxidative Stress in Spinal Cord Injury

Mechanism of Spinal Cord Injury Induced by Decompression Sickness: the Therapeutic Effects of NGF